Healthcare Industry News: heart valve therapy
News Release - May 2, 2008
CoreValve Names Vito A. Canuso III as Vice President, Intellectual PropertyIRVINE, Calif.--(HSMN NewsFeed)--CoreValve (www.corevalve.com) announced today that it has appointed Vito A. Canuso III as Vice President, Intellectual property. In this position, Mr. Canuso’s immediate focus will include managing the worldwide patent litigation with Edwards Lifesciences. He also will assume responsibilities for expanding CoreValve’s global patent portfolio and for developing IP strategies that are intended to enhance CoreValve’s growing leadership position in the transcatheter heart valve therapy market.
Mr. Canuso joins CoreValve from one of the largest intellectual property law firms in the United States—Knobbe, Martens, Olson & Bear (KMOB), LLP—where he has been a Partner since 1995, as well as a senior member of the firm’s IP Litigation Department and its Patent Prosecution Department. Mr. Canuso is registered to practice before the U.S. Patent and Trademark office and a member of the State Bar of California. He received his law degree in 1990 from the University of San Diego. Additionally, he holds a bachelor’s degree in mechanical engineering from Villanova University and a master’s degree in civil engineering from the University of Notre Dame.
“Vito Canuso has litigated cases before numerous district courts across the U.S. and has handled and argued appeals to the Federal Circuit Court of Appeals. Additionally, he has tried a case before the International Trade Court in Washington, D.C.,” said Jacques Séguin, M.D., Ph.D., Chairman and Founder of CoreValve. “Certainly, his significant experience and proven medical specialty device expertise are expected to serve CoreValve well as the Company asserts its intellectual property and legal rights relating to its proprietary ReValving® System for transcatheter aortic valve replacement in high-risk patients.”
CoreValve, Inc., is headquartered in Irvine, Calif. Its proprietary ReValving® System allows both percutaneous aortic valve replacement (PAVR) and transapical aortic valve replacement (TAVR) and is intended to provide an alternative to open-heart surgery. The ReValving® System procedures are performed on the beating heart without cardiac assistance or rapid pacing, and may result in less trauma to the patient. This technology may also offer substantial cost-savings to the healthcare system. The catheter-based technology includes a proprietary framed/self-expanding tissue heart valve that is specifically designed and engineered for transcatheter delivery. For more information about CoreValve, visit the Company’s Web site at www.corevalve.com.
(Caution: the CoreValve ReValving System will not be available in the USA for clinical trials or for sale until further notice.)
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.